Companies
Cresilon
its biomimetic hemostatic gel, marketed as TraumaGel, showed promising results for treating penetrating traumatic brain injury in a study with the Walter Reed Army Institute of Research, received an Innovative Technology contract from Vizient, and was named to Fast Company's Most Innovative Companies list for 2026.
- Country
- United States
Hemostatic gel
Trauma/TBI validated
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $158.3M total funding (2026-04-29) | commercialobserver.com |
| Capacity | 55,000 square foot biomanufacturing facility in Brooklyn (2026-03-01) | commercialobserver.com · biospace.com |
| Regulatory approval | FDA 510(k) clearance for TRAUMAGEL for temporary external use to control moderate to severe bleeding (2024-08-15) | cresilon.com · ijpsjournal.com |
| Regulatory approval | FDA 510(k) clearance for Cresilon Hemostatic Gel (CHG) for local management of minor bleeding wounds (2023-06-01) | cresilon.com · prnewswire.com |
| Headcount | approximately 92 employees (2026-07-01) | commercialobserver.com |
| Revenue | $3.0M annual revenue (2025-01-01) medium confidence | zippia.com |
| Production site | 55,000 square foot facility in Brooklyn's Industry City (2026-03-01) | commercialobserver.com |
Independent sources: biospace.com · commercialobserver.com · ijpsjournal.com · prnewswire.com · zippia.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biomimetic medical adhesives | regenerative-personalized | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.